- Home
- HSPO vs MIST Comparison
HSPO vs MIST Comparison
Compare HSPO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- MIST
- Stock Information
- Founded
- HSPO 2014
- MIST 2003
- Country
- HSPO United States
- MIST Canada
- Employees
- HSPO N/A
- MIST N/A
- Industry
- HSPO Blank Checks
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- MIST Health Care
- Exchange
- HSPO Nasdaq
- MIST Nasdaq
- Market Cap
- HSPO 87.7M
- MIST 81.5M
- IPO Year
- HSPO 2022
- MIST N/A
- Fundamental
- Price
- HSPO $11.25
- MIST $1.43
- Analyst Decision
- HSPO
- MIST Strong Buy
- Analyst Count
- HSPO 0
- MIST 3
- Target Price
- HSPO N/A
- MIST $13.00
- AVG Volume (30 Days)
- HSPO 27.4K
- MIST 177.8K
- Earning Date
- HSPO 01-01-0001
- MIST 11-11-2024
- Dividend Yield
- HSPO N/A
- MIST N/A
- EPS Growth
- HSPO N/A
- MIST N/A
- EPS
- HSPO 0.33
- MIST N/A
- Revenue
- HSPO N/A
- MIST N/A
- Revenue This Year
- HSPO N/A
- MIST N/A
- Revenue Next Year
- HSPO N/A
- MIST N/A
- P/E Ratio
- HSPO $34.26
- MIST N/A
- Revenue Growth
- HSPO N/A
- MIST N/A
- 52 Week Low
- HSPO $10.60
- MIST $1.12
- 52 Week High
- HSPO $11.25
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- MIST 42.50
- Support Level
- HSPO $11.17
- MIST $1.41
- Resistance Level
- HSPO $11.25
- MIST $1.53
- Average True Range (ATR)
- HSPO 0.00
- MIST 0.07
- MACD
- HSPO 0.00
- MIST -0.01
- Stochastic Oscillator
- HSPO 100.00
- MIST 26.96
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).